MERIT MEDICAL SYSTEMS INC(MMSI)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
MERIT MEDICAL SYSTEMS INC (MMSI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MMSI at 64.0/100 on a 32-signal composite quality model, placing it at rank #583 of 2,961 stocks — the top 25% of the AI-ranked universe. MMSI scores in the top quartile across earnings quality (82.9), institutional flow (75.6). Shareholder dilution risk is elevated at 33.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MERIT MEDICAL SYSTEMS INC reports quarterly revenue of $418.8M, net income of $38.8M, an operating margin of 14.4%. Top institutional holders of MMSI by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MMSI trades on the Nasdaq exchange and files with the SEC under CIK 856982. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MMSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MERIT MEDICAL SYSTEMS INC directly from SEC EDGAR.
AI Quality Score
64.0/100
AI Rank
#583
Revenue
$418.8M
Net Income
$38.8M
Free Cash Flow
$51.9M
Operating Margin
14.4%
MMSI key financials by period
MERIT MEDICAL SYSTEMS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.5B
$128.5M
12.2%
FY 2024
10-K
$1.4B
$120.4M
11.5%
FY 2023
10-K
$1.3B
$94.4M
9.9%
FY 2022
10-K
$1.2B
$74.5M
7.6%
FY 2021
10-K
$1.1B
$48.5M
5.7%
FY 2020
10-K
$963.9M
$-9.8M
-0.2%
Institutions holding MMSI
Institutional investors reporting a position in MERIT MEDICAL SYSTEMS INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Merit Medical reported Q2 revenue of $418.8M (+9.5% YoY) with net income of $38.8M (+19% YoY), driven by strong growth in therapeutic products and improved gross margins.
Biggest Revenue Drivers
Foundational$281.0M+7.1% YoY
Access platform increased 6.4% from hemostasis products and angiography; Vascular Intervention up 19.2%; offset by Procedural Solutions decline from DualCap divestiture.
Therapeutic$137.9M+14.8% YoY
Cardiac Therapies up 24.3% from lead management and pacing products; Endoscopy up 28.5% from C2 Cryoballoon acquisition and EsophyX device.
Biggest Revenue Drivers
Total revenue: $418.8M+9.5% YoY
Foundational$281.0M+7.1% YoY
Access platform increased 6.4% from hemostasis products and angiography; Vascular Intervention up 19.2%; offset by Procedural Solutions decline from DualCap divestiture.
Therapeutic$137.9M+14.8% YoY
Cardiac Therapies up 24.3% from lead management and pacing products; Endoscopy up 28.5% from C2 Cryoballoon acquisition and EsophyX device.
Largest Expense Items
Cost of sales$203.7M+2.9% YoY
Partially offset by $6.9M in IEEPA tariff refunds and favorable product mix.
Selling, general and administrative$129.2M+14.3% YoY
Increased by commissions on sales growth, headcount additions, stock-based compensation, and $5.6M View Point acquisition-related costs.
Research and development$25.4M+4.2% YoY
Increase primarily due to merit-based salary increases effective in Q2 2026.
Margins: Gross profit margin expanded to 51.4% from 48.2% YoY, driven by sales growth, favorable product mix, and approximately $6.9M in IEEPA tariff refunds. Operating margin improved to 14.4% from 12.3% YoY despite higher SG&A expenses.
Watch Items from the Filing
Convertible Notes due 2029 totaling $747.5M at 3.00% interest; Merit paid $5.1M additional interest in Q2 2026 for failure to timely remove restrictive legends; notes restrict operational flexibility and incur $12.1M quarterly interest expense.
Three recent acquisitions (View Point $137M net in April 2026, C2 Cryoballoon $21.9M in November 2025, Biolife $127M in May 2025) create integration risk; View Point had no sales in Q2 2026 pending commercialization.
Domestic revenue grew 11.0% to $252.1M (60.2% of sales); international revenue grew 7.3% to $166.8M; geopolitical risks including U.S.-Israel-Iran conflict could disrupt supply chains and increase commodity costs.
Company divested DualCap product line in February 2026 for $28M with $12.5M pre-tax gain; obligated to perform contract manufacturing and transition services for up to 24 months post-close.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
